How TAKHZYRO works
As you may know, people with hereditary angioedema (HAE) don’t have enough C1-inhibitor protein, or the C1-inhibitor protein doesn’t work properly. This causes another protein, plasma kallikrein, to become overactive. This increase in kallikrein activity results in too much bradykinin, the substance that causes HAE attacks. TAKHZYRO decreases kallikrein activity.
What should I know about TAKHZYRO and side effects?
The safety of TAKHZYRO was assessed in one of the longest prevention studies in HAE. See common side effects experienced by people in the study and ask your doctor any questions you have.